solute carrier family 30 member 10Genealiases: HMDPC · HMNDYT1 · ZNT10 · ZNT8 · ZRC1 · ZnT-10
Q-omics provides the consensus-scored SLC30A10 profile across patient tissues and cancer cell-line models. SLC30A10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC30A10 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, SLC30A10 RNA expression shows 15,811 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where SLC30A10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC30A10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC30A10 survival associations across molecular data types. SLC30A10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC30A10 RNA expression–survival associations across cancer types. High SLC30A10 expression shows unfavorable associations in ACC, BLCA, THCA, KIRC and CHOL, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC30A10 RNA expression.
This table summarizes SLC30A10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SLC30A10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC30A10 shows lower tumor expression in COAD, THCA, KICH and READ and higher tumor expression in LIHC and LUAD. The COAD box plot shows higher SLC30A10 RNA expression in normal versus tumor tissue (log2 FC = −3.564, t-test p < 0.001).
This table shows molecular features associated with SLC30A10 in patient tissues and cancer cell lines. In patient samples, SLC30A10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC30A10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LIVER.
